Nonsteroidal anti-inflammatory drugs and change in mammographic density: A cohort study using pharmacy records on over 29,000 postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 5, 2008, Pages 1088-1095

  Terry, Mary Beth ^a,b   Buist, Diana S M ^c   Trentham Dietz, Amy ^d   James Todd, Tamarra M ^a   Liao, Yuyan ^a  

^a Mailman School of Public Health   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CLASSIFICATION; CONFIDENCE INTERVAL; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MEDICAL RECORD; PHARMACY; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL MODEL; BREAST; BREAST TUMOR; COHORT ANALYSIS; DRUG EFFECT; MIDDLE AGED; QUESTIONNAIRE; RADIOGRAPHY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BREAST; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; QUESTIONNAIRES;

EID: 52649119824     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2836     Document Type: Article

References (58)

1. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
2. Bardia A, Ebbert JO, Vierkant RA, et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. J Natl Cancer Inst 2007;99:881-9.
3. Carter CA, Milholland RJ, Shea W, Ip MM. Effect of the prostaglandin synthetase inhibitor indomethacin on 7,12-dimethylbenz(a) anthracene-induced mammary tumorigenesis in rats fed different levels of fat. Cancer Res 1983;43:3559-62.
4. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
5. Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291:2433-40.
6. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
7. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995;24:107-9.
8. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999;6:71-3.
9. Harris RE, Namboodiri K, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 1995;24:119-20.
10. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996;7:203-5.
11. Coogan PF, Rao SR, Rosenberg L, et al. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999;29:72-6.
12. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000;83:112-20.
13. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1213-7.
14. Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:1586-91.
15. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
16. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005;68:40-7.
17. Slattery ML, Curtin K, Baumgartner R, et al. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007;16:747-55.
18. Gallicchio L, McSorley MA, Newschaffer CJ, et al. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006;106:1443-52.
19. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006;6:27.
20. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005;5:159.
21. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005;162:165-70.
22. Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer 2004;91:525-9.
23. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000;320:1642-6.
24. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
25. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996;88:988-93.
26. Jacobs EJ, Thun MJ, Connell CJ, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005;14:261-4.
27. Marshall SF, Bernstein L, Anton-Culver H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005;97:805-12.
28. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
29. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-36.
30. Boyd NF, Martin LJ, Yaffe MJ, Minkin S. Mammographic density: a hormonally responsive risk factor for breast cancer. J Br Menopause Soc 2006;12:186-93.
31. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808.
32. Pike MC. The role of mammographic density in evaluating changes in breast cancer risk. Gynecol Endocrinol 2005;21 Suppl 1:1-5.
33. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995;87:670-5.
34. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-95.
35. Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993;15:196-208.
36. Gram IT, Funkhouser E, Tabar L. Moderate physical activity in relation to mammographic patterns. Cancer Epidemiol Biomarkers Prev 1999;8:117-22.
37. Nordevang E, Azavedo E, Svane G, Nilsson B, Holm LE. Dietary habits and mammographic patterns in patients with breast cancer. Breast Cancer Res Treat 1993;26:207-15.
38. Lundstrom E, Wilczek B, von Palffy Z, Soderqvist G, von Schoultz B. Mammographic breast density during hormone replacement therapy: differences according to treatment. Am J Obstet Gynecol 1999;181:348-52.
39. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic densities and risk of breast cancer among subjects with a family history of this disease. J Natl Cancer Inst 1999;91:1404-8.
40. Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ. Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:1133-44.
41. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
42. Bjurstam N, Bjorneld L, Duffy SW, et al. The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 1997;80:2091-9.
43. Chan SM, Nelson EA, Leung SS, Cheng JC. Bone mineral density and calcium metabolism of Hong Kong Chinese postpartum women - a 1-y longitudinal study. Eur J Clin Nutr 2005;59:868-76.
44. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Post-menopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-9.
45. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis is proximal to a breast tumor is stimulated by PGE2 via cyclic AMP leading to activation of promoter II of the CYP 19 (aromatase) gene. Endocrinology 1996;137:5739-42.
46. Elvin JA, Yan C, Matzuk MM. Growth differentiation factor-9 stimulates progesterone synthesis in granulose cells via a prostaglandin E2/EP2 receptor pathway. Proc Natl Acad Sci U S A 2000;97:10288-93.
47. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-6.
48. Taplin SH, Mandelson MT, Anderman C, et al. Mammography diffusion and trends in late-stage breast cancer: evaluating outcomes in a population. Cancer Epidemiol Biomarkers Prev 1997;6:625-31.
49. Taplin SH, Ichikawa L, Buist DS, Seger D, White E. Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev 2004;13:225-34.
50. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004;104:1042-50.
51. American College of Radiology. The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). 4th ed. Reston (VA): American College of Radiology; 2003.
52. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 1996;276:33-8.
53. Ooms EA, Zonderland HM, Eijkemans MJ, et al. Mammography: interobserver variability in breast density assessment. Breast 2007;16:568-76.
54. Ciatto S, Houssami N, Apruzzese A, et al. Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories. Breast 2005;14:269-75.
55. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons; 1989.
56. Tamimi RM, Byrne C, Colditz GA, Hankinson SE. Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2007;99:1178-87.
57. Tamimi RM, Hankinson SE, Colditz GA, Byrne C. Endogenous sex hormone levels and mammographic density among post-menopausal women. Cancer Epidemiol Biomarkers Prev 2005;14:2641-7.
58. Maskarinec G, Urano Y, Gill J, Kolonel LN. Nonsteroidal anti-inflammatory drugs (NSAIDs) and mammographic density. Breast Cancer Res Treat 2007. Online only [epub ahead of print] 2007 Nov 29; 1-7.